Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Brenda J. Weigel, Keith D. Wilner, David Hall, Charles G. Minard, Jennifer Foster, Peter C. Adamson, Stacey L. Berg, Elizabeth Fox, Susan M. Blaney, Stephan D. Voss, Yael P. Mosse, Frank M. Balis
Publikováno v:
Clinical Cancer Research. 27:3543-3548
Purpose: Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor crizotinib in patients with no known curative treatments and whose tumors harbore
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Jan H. Beumer, Huichen Feng, Ashwin Reddy Sama, Thomas J. George, Corey Lipchik, Carmen J. Allegra, Melanie Finnigan, Philip J. Stella, James L. Wade, Katherine L. Pogue-Geile, Ying Wang, Patrick G. Gavin, Ashok Srinivasan, James J. Lee, Rim S. Kim, Norman Wolmark, Brian F. Kiesel, Peter C. Lucas, Fanny Piette, Samuel A. Jacobs, Ding Wang
Publikováno v:
Clinical Cancer Research. 27:1612-1622
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combin
Autor:
Amy Zhang, Grainne M. O'Kane, Paz Polak, Celia M. T. Greenwood, James Joseph Biagi, Sandra Fischer, Julie M. Wilson, Louis-Martin Boucher, Gun Ho Jang, Zu-Hua Gao, Jennifer J. Knox, Yifan Wang, Yasser Riazalhosseini, Nathaniel Bouganim, Ayelet Borgida, David Valenti, Robert C. Grant, Steven Gallinger, Mehdi Masoomian, Robert E. Denroche, William D. Foulkes, John M. S. Bartlett, Chani Stossel, Maria Raitses-Gurevich, Alain Pacis, Ilinca Lungu, Talia Golan, Simeng Bu, Jean Monlong, T. Cabrera, George Zogopoulos, Celine Domecq, Spring Holter, Jin Yong Patrick Park, Jamil Asselah, Adeline Cuggia
Publikováno v:
WAng, Y, Patrick Park, J Y, Pacis, A, E. Denroche, R, Jang, G H, Zhang, A, Cuggia, A, Domecq, C, Monlong, J, Raitses-Gurevich, M, C. Grant, R, Borgida, A, Holter, S, Stossel, C, Bu, S, Masoomian, M, Lungu, I, Bartlett, J, M. Wilson, J, Gao, Z-H, Riazalhosseini, Y, Asselah, J, Bouganim, N, Cabrera, T, Boucher, L-M, Valenti, D, Biagi, J, M.T Greenwood, C, Polak, P, D. Foulkes, W, Golan, T, M. O'Kane, G, E. Fischer, S, J. Knox, J, Gallinger, S & Zogopoulos, G 2020, ' A preclinical trial and molecularly-annotated patient cohort identify predictive biomarkers in homologous recombination deficient pancreatic cancer ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-20-1439
Purpose:Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is
Autor:
Byong Chang Jeong, Hyun Hwan Sung, Antonio Gualberto, Se Hoon Park, Ghee Young Kwon, Hye Won Lee, Han Yong Choi, Catherine Scholz, Jason K. Sa
Publikováno v:
Clinical Cancer Research. 26:5113-5119
Purpose:To assess the antitumor activity and safety of tipifarnib, a highly potent and selective farnesyltransferase inhibitor, we performed a phase II clinical trial in patients with advanced and refractory urothelial carcinoma harboring missense HR
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai